Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho to Ask for Development of 109 Drugs/Indications
May 17, 2010
- Lixisenatide Significantly Reduces HbA1c: sanofi-aventis
May 17, 2010
- 68% of Public “Don't Know About HPV” Survey
May 17, 2010
- WG to Discuss Regulatory Requirements for Regenerative Medicine
May 17, 2010
- Merck Serono Begins Infertility Treatment Education Program
May 17, 2010
- Exforge to Compete with Takeda's Unisia: Mr Anderson of Novartis
May 17, 2010
- GRU to Call For Lifting on Ban on Supply of Information on Unapproved Drugs
May 17, 2010
- New JMA Leadership to Follow Former Leadership's Policies
May 17, 2010
- Janssen: Sales Up 2.7% to ¥80.5 Bil.
May 17, 2010
- Takeda Applies for Successor of Blopress in the US
May 17, 2010
- Good Control of Nocturnal Respiratory Symptoms Important in Children: Prof. Mochizuki
May 17, 2010
- Torii to Boost Sales to ¥50 Bil. by FY2012
May 17, 2010
- Eisai Applies for Reflux Esophagitis for Pariet
May 17, 2010
- Treatment Cost Holds Key in Selection of ARB/CCB Combinations: Dr Ogihara
May 17, 2010
- METI Presents Report on Pharma Industry Promotion
May 17, 2010
- Abbott Japan Applies for Kaletra for Once Daily Treatment
May 17, 2010
- Chugai to Educate Top Oncology MRs
May 17, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? (1)
May 17, 2010
- DSP's Eslicarbazepine Not Approved by FDA
May 17, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? (2)
May 17, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…